Clinical trial · Interventional
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
Towards Optimal Personalized Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate if the proportion of neuroendocrine tumor (NET) patients with normal vitamin values can be increased, with vitamin suppletion and a personalized diet, Effects of the intervention will be evaluated by quantitative analysis of blood and urine and questionnaires. The measurements, will be performed at baseline (t=0), after 4 weeks (t=4) and after 18 weeks at end of study (t=18). Furthermore at t=18 a semi-qualitative interview will be performed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumor | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diet advice | Other | — | UNRESOLVED |
| Vitamin supplement; | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Vitamin supplement and diet advice
- description
- Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
- interventionNames
- Dietary Supplement: Vitamin supplement;
- Other: Diet advice
Primary outcomes (1)
- measure
- the change in the proportion of patients with normal vitamin values
- timeFrame
- 18 weeks
- description
- the change in the proportion of patients with normal vitamin values measured with quantitative analysis of blood and urine
Secondary outcomes (5)
- measure
- nutrition state
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients aged ≥ 18 years * NET-patients with serotonin producing or non-serotonin producing tumors, with gastro-intestinal, pancreatic, bronchopulmonary or unknown primary tumor site and with metastasized or irresectable disease * Ability to comprehend Dutch (both reading and writing). * Written informed consent provided. * Use of somatostatin analogue for \> 6 months. Exclusion Criteria: * Estimated life expectancy less than 6 months. * Patients who have a history of another primary malignancy, except for radical and adequately treated malignancies from which the patient has been disease free for ≥ 1 year. * Major abdominal surgery during study period. * Patients already participated in the DIVIT-pilot study * Known hypersensitivity of (components of) somatostatin analogue
References
Publications (0)
Data not yet available